Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02213926 · ClinicalTrials.gov registry record · Phase 2

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

A Phase 2 study of Mantle Cell Lymphoma (MCL), sponsored by Acerta Pharma.

Active
Registry status
Phase 2
Development phase
124
Enrollment target
20
Study locations

NCT02213926 is a Phase 2 study of Mantle Cell Lymphoma (MCL) that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 124 participants, below the 195-participant average among 9 other Mantle Cell Lymphoma (MCL) trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02213926, a Phase 2 study of Mantle Cell Lymphoma (MCL), is active but no longer recruiting, sponsored by Acerta Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
124 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).

Conditions Studied

Mantle Cell Lymphoma (MCL)

Interventions

  • DRUG ACP-196 (acalabrutinib)

Study Locations (20)

Other

  • Research Site - Monash
  • Research Site - Sydney
  • Research Site - Wodonga
  • Research Site - Bruges
  • Research Site - Brussels
  • Research Site - Brussels
  • Research Site - Liège
  • Research Site - Yvoir
  • Research Site - Prague
  • Research Site - Angers
  • Research Site - Caen

Illinois

  • Research Site - Chicago
  • Research Site - Niles
  • Research Site - Peoria

Florida

  • Research Site - Tampa

Massachusetts

  • Research Site - Boston

New Jersey

  • Research Site - Hackensack

New York

  • Research Site - New York

Texas

  • Research Site - Houston

Washington

  • Research Site - Seattle

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2015-03-02
Est. Completion 2026-09-09
Phase Phase 2

Sponsor

Acerta Pharma

38 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02213926

The ClinicalTrials.gov registry entry for NCT02213926 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 9 other Mantle Cell Lymphoma (MCL) trials with a reported enrollment target (36% lower). The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Mantle Cell Lymphoma (MCL) appearing as the primary indexed condition, and to 1 intervention - of which ACP-196 (acalabrutinib) is the first listed.

NCT02213926 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT02213926 about?

NCT02213926 is a clinical study titled "An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma". The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).

What is the current status of trial NCT02213926?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2015-03-02. Estimated completion is 2026-09-09.

What conditions does trial NCT02213926 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma (MCL).

What interventions are being tested in trial NCT02213926?

The interventions under investigation include: ACP-196 (acalabrutinib) (DRUG).

Who is sponsoring clinical trial NCT02213926?

This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02213926 being conducted?

This trial has 20 study locations across Florida, Illinois, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma (MCL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma (MCL)

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.